SPECIAL FEATURES

Highlights of This Issue 4863

CCR Translations

4865 Detection of NRG1 Fusions in Solid Tumors: Rare Gold?
Anastasios Dimou and D. Ross Camidge
See related article, p. 4966

4868 Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?
Richard T. Pisaczakowski and Ulrich Steidl
See related article, p. 4858

4871 When Cancer Vaccines Go Viral
David Reparaz, Diana Llopiz, and Pablo Sarobe
See related article, p. 4933

CCR Perspectives in Regulatory Science and Policy

4874 Advancing Drug Development in Gynecologic Malignancies
Julia A. Beaver, Robert L. Coleman, Rebecca C. Azend, Deborah K. Armstrong, Sanjeeve Bala, Gordon B. Mills, Anil K. Sood, and Thomas J. Herzog

Review

4881 Redefining Treatment Paradigms in First-line Advanced Non–Small-Cell Lung Cancer
David F. Heigener, Keith M. Kerr, Gavin M. Laing, Tony S.K. Mok, Fedor V. Moiseyenko, and Martin Reck

CLINICAL TRIALS: TARGETED THERAPY

4888 Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastislav Bahleda, Antoine Italiano, Cinta Hierro, Alain Mita, Andres Cervantes, Nancy Chan, Mark Awad, Emiliano Calvo, Victor Moreno, Ramaswamy Govindan, Alexander Spira, Martha Gonzalez, Bob Zhong, Ademi Santiago-Walker, Italo Poggesi, Trilok Parekh, Hong Xie, Jeffrey Infante, and Josep Tabernero

Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
See related commentary, p. 4868

4907 A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia
Irene M. Ghobrial, Ravi Vij, David Siegel, Ashraf Radros, Jonathan Kaufman, Noopur Raje, Andrzeje Jakubowiak, Michael R. Savona, Mihaela Obreja, and Jesus G. Berdeja

4917 Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results

4924 First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity
Hui K. Gan, Michael Millward, Ye Hua, Chuan Qi, Yang Sai, Weiguo Su, Jian Wang, Lilin Zhang, Melanie M. Frigault, Shethah Morgan, Liu Yang, and Jason D. Lickliter

CLINICAL TRIALS: IMMUNOTHERAPY

4933 A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA With Costimulatory Molecules
Margaret E. Gatti-Mays, Julius Strauss, Renee N. Donahue, Claudia Palena, Jaydira Del Rivero, Jason M. Redman, Ravi A. Madan, Jennifer L. Marté, Lisa M. Cordes, Elizabeth Lamping, Alanvin Orpia, Andrea Burmeister, Eva Wagner, Cesar Pico Navarro, Christopher R. Heery, Jeffrey Schom, and James L. Gulley
See related commentary, p. 4871
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion
Kevin C. Conlon, E. Lake Potter, Stefania Pittaluga, Chyi-Chia Richard Lee, Milos D. Miljkovic, Thomas A. Fleisher, Sigrid Dubois, Bonita R. Bryant, Michael Petrus, Liyanage P. Perera, Jennifer Hsu, William D. Figg, Cody J. Peer, Joanna H. Shih, Jason L. Yovandich, Stephen P. Creekmore, Mario Roederer, and Thomas A. Waldmann

A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma

Detection of NRG1 Gene Fusions in Solid Tumors

Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer

Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
Tessa G. Steenbruggen, Maartje van Seijen, Liselore M. Janssen, Mette S. van Ramshorst, Erik van Werkhoven, Marie-Jeanne T.D.F. Vrancken Peeters, Jelle Wesseling, Esther H. Lips, and Gabe S. Sonke

Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data
Steffen Venzt, Albert Lai, Timothy F. Cloughesy, Patrick Y. Wen, Lorenzo Trippa, and Brian M. Alexander

Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer
Yi Xiao, Ding Ma, Shen Zhao, Chen Suo, Jinxiu Shi, Meng-Zhu Xue, Miao Ruan, Hai Wang, Jingjing Zhao, Qin Li, Peng Wang, Leming Shi, Wen-Tao Yang, Wei Huang, Xin Hu, Ke-Da Yu, Shenglin Huang, Francois Bertucci, Yi-Zhou Jiang, and Zhu-Ming Shao; on behalf of AME Breast Cancer Collaborative Group

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Wenfeng Fang, Yuxiang Ma, Jian C. Yin, Shaodong Hong, Huajing Zhou, Ao Wang, Wufeng Wang, Hua Bao, Xue Wu, Yumeng Yang, Yan Huang, Hongrui Zhao, Yang W. Shao, and Li Zhang

Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging
Stephen R. Bowen, Daniel S. Hippe, W. Art Chaovalitwongse, Chunyan Duan, Phawis Thammason, Xiao Liu, Robert S. Miyakura, Hubert J. Vesse, Paul E. Kinahan, Ramesh Rengan, and Jing Zeng

Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia

Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells
Zhe Su, Zhijie Wang, Xiaohui Ni, Jinchun Duan, Yan Gao, Pingfeng Zhuo, Ruoyan Li, Jun Zhao, Qi Ma, Hua Bai, Hengyu Chen, Shuhang Wang, Xixi Chen, Tongtong An, Yuyan Wang, Yanyuan Tian, Jiangyong Yu, Di Wang, Xiaoliang Sunne Xie, Fan Bai, and Jie Wang
ABOUT THE COVER

The cover shows a section of the bone marrow biopsy from a patient with primary myelofibrosis. Reticulin staining shows diffusely increased bone marrow fibrosis, a hallmark of the disease pathology. For details, see the article by Gangat and colleagues on page 4898 of this issue.